Study guide

Epidemiology, calculations, bias and surveillance

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Epidemiology, calculations, bias and surveillance

Key Takeaways Explain This Topic AI

Predictive values change with pre-test probability.

NNT is calculated from absolute risk reduction using the same time horizon.

Randomisation balances confounding in expectation rather than guaranteeing identical groups.

Last updated: October 2026

Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Evidence-based clinical decision-making requires medical practitioners to critically evaluate diagnostic test accuracy, interpret biostatistical parameters, synthesize research study designs, and fulfill statutory obligations in communicable disease surveillance. Mastery of these public health concepts is essential for hospital practice and primary care across Australia.

Diagnostic Test Accuracy & The 2x2 Contingency Matrix

The diagnostic utility of any clinical sign, bedside investigation, or laboratory test is evaluated using a standard 2 × 2 2 \times 2 2 × 2 contingency table comparing test results against a gold-standard diagnostic reference.

Intrinsic Test Parameters: Sensitivity & Specificity

Sensitivity : The probability that a diseased person tests positive: Sensitivity = T P T P + F N \text{Sensitivity} = \frac{TP}{TP + FN} Sensitivity = TP + FN TP ​

Clinical Rule: SnNOut (A test with very high Sn -sitivity, when N -egative, rules Out the disease). Highly sensitive tests produce very few false negatives and are ideal for screening (e.g., D-dimer in low-risk deep vein thrombosis, HIV antibody/antigen testing).

Specificity : The probability that a non-diseased person tests negative: Specificity = T N T N + F P \text{Specificity} = \frac{TN}{TN + FP} Specificity = TN + FP TN ​

Clinical Rule: SpPIn (A test with very high Sp -ecificity, when P -ositive, rules In the disease). Highly specific tests produce very few false positives and are ideal for confirmation (e.g., Western blot, biopsy histopathology, target-specific PCR).

Test characteristics: Sensitivity and specificity are conditional on disease status rather than calculated directly from prevalence. They can nevertheless vary across populations because of disease spectrum, threshold, sampling and verification. Predictive-value comparisons assume the operating characteristics are held constant.

Extrinsic Test Parameters: Predictive Values & Prevalence

Unlike sensitivity and specificity, predictive values depend heavily on the prevalence of the disease in the population being tested:

Positive Predictive Value (PPV) : The probability that a patient with a positive test result truly has the disease: PPV = T P T P + F P \text{PPV} = \frac{TP}{TP + FP} PPV = TP + FP TP ​

Negative Predictive Value (NPV) : The probability that a patient with a negative test result is truly disease-free: NPV = T N T N + F N \text{NPV} = \frac{TN}{TN + FN} NPV = TN + FN TN ​

Likelihood Ratios & Fagan's Nomogram

Likelihood ratios (LRs) quantify the degree to which a given diagnostic test result shifts the pre-test odds into post-test odds. Unlike predictive values, likelihood ratios are independent of disease prevalence :

Positive Likelihood Ratio ( LR + \text{LR}^+ LR + ) : How much the odds of disease increase when a test is positive: LR + = Sensitivity 1 − Specificity = True Positive Rate False Positive Rate \text{LR}^+ = \frac{\text{Sensitivity}}{1 - \text{Specificity}} = \frac{\text{True Positive Rate}}{\text{False Positive Rate}} LR + = 1 − Specificity Sensitivity ​ = False Positive Rate True Positive Rate ​

Likelihood-ratio interpretation: A large LR shifts odds substantially, but the resulting probability still depends on the pre-test odds. A positive LR above 10 does not make a rare diagnosis certain, and a negative LR below 0.1 does not erase a very high prior probability.

An LR + \text{LR}^+ LR + between 5 and 10 generates moderate diagnostic shifts.

An LR + \text{LR}^+ LR + between 2 and 5 generates small, borderline shifts.

Negative Likelihood Ratio ( LR − \text{LR}^- LR − ) : How much the odds of disease decrease when a test is negative: LR − = 1 − Sensitivity Specificity = False Negative Rate True Negative Rate \text{LR}^- = \frac{1 - \text{Sensitivity}}{\text{Specificity}} = \frac{\text{False Negative Rate}}{\text{True Negative Rate}} LR − = Specificity 1 − Sensitivity ​ = True Negative Rate False Negative Rate ​

An LR − \text{LR}^- LR − between 0.1 and 0.2 generates moderate diagnostic reductions.

Clinical Application : Post-test Odds = Pre-test Odds × LR \text{Post-test Odds} = \text{Pre-test Odds} \times \text{LR} Post-test Odds = Pre-test Odds × LR . Clinicians can map pre-test probability to post-test probability at the bedside using a Fagan nomogram.

Clinical Study Designs & Measures of Association

Evidence-based practice stratifies clinical research along an established hierarchy of methodological rigor.

1. Randomized Controlled Trials (RCTs)

Randomisation: Balances confounders in expectation, not necessarily exactly in a finite trial. Allocation concealment prevents foreknowledge influencing recruitment; blinding addresses other biases. Describe who was blinded rather than relying on an ambiguous “double-blind” label.

Blinding : Single-blind (participants unaware), double-blind (participants and investigators/clinicians unaware), or triple-blind (participants, clinicians, and data analysts unaware). Prevents performance bias and detection bias.

Intention to treat: Analyse according to randomised assignment where possible, but report missing outcomes and sensitivity analyses. ITT alone does not eliminate bias from differential loss to follow-up; per-protocol analyses answer a different question and can be confounded.

2. Cohort Studies (Prospective or Retrospective)

Design : Participants are classified according to their exposure status (exposed vs unexposed) and followed forward in time to observe the incidence of the outcome/disease.

Strengths : Best design to establish temporality, calculate true disease incidence, and evaluate rare exposures or multiple outcomes from a single exposure.

Measure of Association : Relative Risk (Risk Ratio, RR) : RR = Incidence in exposed Incidence in unexposed = a / ( a + b ) c / ( c + d ) \text{RR} = \frac{\text{Incidence in exposed}}{\text{Incidence in unexposed}} = \frac{a / (a+b)}{c / (c+d)} RR = Incidence in unexposed Incidence in exposed ​ = c / ( c + d ) a / ( a + b ) ​

RR = 1 \text{RR} = 1 RR = 1 : No association between exposure and outcome.

RR > 1 \text{RR} > 1 RR > 1 : Exposure increases disease risk.

RR < 1 \text{RR} < 1 RR < 1 : Exposure is protective against the disease.

3. Case-Control Studies

Design : Retrospective study where participants are selected based on outcome status (cases have the disease, controls do not); investigators examine past records to determine prior exposure.

Strengths : Highly efficient and economical for rare diseases (e.g., rare malignancies) or diseases with very long latency periods (e.g., mesothelioma from asbestos exposure).

Limitation : Cannot calculate true disease incidence because the ratio of cases to controls is determined arbitrarily by the investigator. Therefore, Relative Risk cannot be directly calculated.

Measure of Association : Odds Ratio (OR) : OR = Odds of exposure in cases Odds of exposure in controls = a / c b / d = a × d b × c \text{OR} = \frac{\text{Odds of exposure in cases}}{\text{Odds of exposure in controls}} = \frac{a / c}{b / d} = \frac{a \times d}{b \times c} OR = Odds of exposure in controls Odds of exposure in cases ​ = b / d a / c ​ = b × c a × d ​

The Rare Disease Assumption : When the prevalence of the disease in the general population is low ( < 5 % < 5\% < 5% ), the Odds Ratio closely approximates the Relative Risk ( OR ≈ RR \text{OR} \approx \text{RR} OR ≈ RR ).

4. Cross-Sectional Studies

Evaluates exposure status and disease status simultaneously at a single cross-sectional point in time.

Cross-sectional measures: Estimate prevalence, not new-case incidence directly. Prevalence is approximately incidence rate × average duration only under steady-state and other assumptions; it is not a universal identity for a changing epidemic.

Biostatistical Measures: ARR, RRR, NNT & NNH

When evaluating clinical trials comparing an intervention group (Experimental Event Rate, EER) against a control group (Control Event Rate, CER):

Absolute Risk Reduction (ARR) : The absolute difference in event rates between groups: ARR = CER − EER \text{ARR} = \text{CER} - \text{EER} ARR = CER − EER

Relative Risk Reduction (RRR) : The proportional reduction in event rate relative to control: RRR = CER − EER CER = ARR CER = 1 − RR \text{RRR} = \frac{\text{CER} - \text{EER}}{\text{CER}} = \frac{\text{ARR}}{\text{CER}} = 1 - \text{RR} RRR = CER CER − EER ​ = CER ARR ​ = 1 − RR

Number Needed to Treat (NNT) : The number of patients who must receive the intervention over a specified duration to prevent one additional adverse outcome: NNT = 1 ARR = 1 CER − EER \text{NNT} = \frac{1}{\text{ARR}} = \frac{1}{\text{CER} - \text{EER}} NNT = ARR 1 ​ = CER − EER 1 ​

Calculation Rule : NNT must always be rounded up to the nearest whole integer.

Number Needed to Harm (NNH) : The number of patients who must receive the intervention to cause one additional adverse event: NNH = 1 Absolute Risk Increase (ARI) = 1 EER − CER \text{NNH} = \frac{1}{\text{Absolute Risk Increase (ARI)}} = \frac{1}{\text{EER} - \text{CER}} NNH = Absolute Risk Increase (ARI) 1 ​ = EER − CER 1 ​

Reporting NNH: State the absolute risk increase, follow-up period and calculation transparently. Report suitable precision; rounding down is not a universal mandatory statistical convention.

Methodological Biases in Clinical Research

Selection Bias : Systematic difference in how participants are selected or retained in a study (e.g., Berkson bias , where hospitalized patients have higher rates of multiple comorbidities; healthy worker effect ).

Recall Bias : Differential accuracy of historical memory between cases and controls. Individuals diagnosed with severe disease (e.g., congenital malformations, cancer) search their memories and over-report past potential exposures compared to healthy controls. Major flaw of case-control studies.

Confounding : A third variable that is independently associated with the exposure AND independently associated with the outcome, without being an intermediate step on the causal pathway. Controlled by randomization, matching, restriction, stratification, or multivariate regression.

Lead-Time Bias : Screening detects disease earlier in its natural history without postponing the actual date of death, artificially inflating calculated survival times from diagnosis without conferring clinical survival benefit.

Length-Time Bias : Screening preferentially detects slowly progressive, indolent conditions with long asymptomatic phases, while rapidly progressive, lethal cases manifest between screening rounds (interval cases), artificially making screened cases appear to have superior outcomes.

Communicable disease surveillance

Notification duties originate in state/territory public-health law. Clinicians report to that health authority; it contributes to the National Notifiable Diseases Surveillance System. Required case definitions, reporter responsibilities and deadlines vary, so a single national urgent/routine timetable is misleading.

Call the PHU urgently for suspected invasive meningococcal disease or measles while beginning appropriate treatment/isolation. Do not wait for serotyping or final culture. Measles contacts can benefit from time-sensitive MMR or immunoglobulin when appropriate; the PHU determines eligibility and timing. Meningococcal prophylaxis is for defined close contacts, not everyone who shares a building.

Rabies/lyssavirus exposure needs immediate wound care and expert PEP assessment. TB, Legionella, hepatitis A and other conditions can require urgent local action rather than a routine five-to-seven-day letter. A notifiable-disease report does not replace infection control, contact precautions or clinical resuscitation. Disclose necessary information under the lawful pathway and document the advice received.

Primary references (checked 7 October 2026): Australian CDC surveillance .